Summary A commonly used technique for evaluating potential bioreductive drugs is the determination of hypoxic cytotoxicity ratios in vitro. This experimental model, however, does not accurately mimic the tumour microenvironment, as other factors (such as reduced pH, poor nutrient status, low cell proliferation rates and high catabolite concentrations) are not incorporated into the design of the assay. Plateau-phase monolayer cultures possess many of these characteristics, and this study compared the response of plateau-phase and exponentially growing human colon carcinoma cells (DLD-1) with a series of standard and bioreductive compounds. All drugs tested were added directly to conditioned medium and three patterns of chemosensitivity were observed. In the case of doxorubicin, vinblastine and 5-fluorouracil, exponentially growing cells were significantly more responsive than plateau-phase cultures. ThioTEPA and MeDZQ (2,5-diaziridinyl-1,4-benzoquinone) were equally cytotoxic to both populations of cells. Tirapazamine (SR4233), RSU 1069, mitomycin C and EO-9, however, were preferentially toxic towards plateau-phase compared with exponentially growing cells. While the exact mechanisms responsible for these observations in each case are not known, this study suggests that plateau-phase cultures may prove to be a useful experimental model in the evaluation of drugs designed to work preferentially within the tumour microenvironment.
A characteristic feature of many solid tumours is that their vascular supply is inadequate leading to regions of the tumour that are poorly perfused with blood (Thomlinson and Gray, 1955; Denekamp, 1986) . This property of solid tumours introduces several factors that reduce the effectiveness of both chemotherapy and radiotherapy. These include gradients of oxygen tension, extracellular pH, nutrients, catabolites, altered expression of biologically and pharmacologically important proteins and cell proliferation rates, all of which vary as a function of distance from a supporting blood vessel (Denekamp, 1986; Sutherland, 1988; Vaupel et al, 1989; Brown and Garccia, 1994) . Tumour cells that reside some distance away from a blood vessel therefore exist in a microenvironment which is quite distinct from normal physiological conditions, and there is considerable interest in trying to exploit this physiological difference to obtain a selective therapy for solid tumours (Kennedy, 1987; Tannock and Rotin, 1989; Gerweck and Seetharaman, 1996) .
A number of strategies have been employed to try and eradicate these cells, particularly with the development of bioreductive drugs which are prodrugs that are enzymatically reduced to cytotoxic species under hypoxic conditions (Brown and Garccia, 1994; Workman, 1994) . Several hypoxic cell cytotoxins have been developed, such as tirapazamine and RSU 1069, which were identified largely on the basis of differential response of cells under air and nitrogen (Zeman et al, 1986; Brown, 1993; Workman and Stratford, 1993) . The only variable assayed in these studies is the oxygenation status of the cultures at the time of drug exposure and, in this respect, the model only partly mimics the conditions found within the microenvironment of tumours (Stratford et al, 1990) . Drugs which are activated by conditions other than hypoxia (e.g. by acidic pH) may be missed, and there is therefore considerable merit in using experimental models that closely mimic the tumour microenvironment in its entirety to identify compounds of this class. Any compounds identified using such a model could be classified as 'bioactivated drugs' as opposed to bioreductive drugs as several factors may contribute towards cytotoxicity, not just hypoxia. Multicellular spheroids and post-confluent multicell layers (Durand and Olive, 1992; Pizao et al, 1993) closely mimic conditions found within solid tumours, although both techniques are labour intensive and are not suitable as a front line screen for bioactivated pro-drugs. There is therefore a need to develop new experimental models of the tumour microenvironment that retain the simplicity required for the in vitro evaluation of large numbers of potential prodrugs.
In the early 1970s, considerable interest centred upon the use of plateau-phase monolayer cultures as an in vitro model of the noncycling fraction of cells that exist within solid tumours, and numerous studies have compared the response of plateau-phase cells with cells in exponential growth to both radiotherapy and chemotherapy (Hahn and Little, 1972; Twentyman and Bleehen, 1973; Barranco and Novak, 1974; Drewinko et al, 1981) . Plateauphase cultures have been extensively characterized and, in addition to a reduction in cellular proliferation rates, a decrease in extracellular pH, oxygen tension and nutrient status plus an increase in lactic acid and catabolite concentrations have been described (Hahn and Little, 1972; Glinos et al, 1973; Mauro et al, 1974; Bhuyan et al, 1977) . These characteristics of plateau-phase cultures, therefore, closely resemble those found within the values (concentration required to kill 50% of the cell population), and all assays were performed in triplicate.
RESULTS

Growth characteristics of DLD-1 cells
Growth curves for DLD-1 cells together with the change in extracellular pH and mitotic indices are presented in Figure 1 . Following an initial lag phase of 24 h, DLD-1 cells entered exponential growth (population doubling time of 21 h) and reached plateau phase on day 6 ( Figure 1A ). Extracellular pH decreased from 7.5 ± 0.2 on day 0 to 6.7 ± 0.15 on day 8 of the growth curve ( Figure IB) . Mitotic indices reached a peak on day 3 (4.73+ 0.38%) and progressively decreased to 0.49 ± 0.21% on day 8 ( Figure IC ).
Chemosensitivity studies
The response of DLD-1 cells exposed to doxorubicin and EO-9 at various stages of the growth curve are presented in Figure 2 . As cells progressed through the growth curve, resistance to doxorubicin increased (Figure 2A ), particularly between days 4 and 7 of the growth curve. In the case of EO-9, DLD-1 cells progressively became more sensitive as cultures matured into plateau phase ( Figure 2B) . A comparison between the response of cells in early exponential growth (day 2) and plateau phase (day 7) to a series of compounds is presented in Figure 3 . Three patterns of chemosensitivity were observed. In the case of doxorubicin, vinblastine and 5-fluorouracil exponentially growing cells were significantly more responsive than the same cells in plateau phase ( Figure 3A ). ThioTEPA and MeDZQ were equally effective against plateau-phase cells as exponentially growing cells ( Figure  3B ). Finally, EO-9, mitomycin C, tirapazamine and RSU 1069 were preferentially cytotoxic towards plateau-phase cultures compared with exponentially growing cells ( Figure 3C ).
DISCUSSION
The principal objective of this study was to develop a novel cellbased screening assay that could be used to identify drugs that are activated under conditions which mimic the tumour microenvironment. Plateau-phase cultures closely mimic the microenvironment of tumours, in that cell proliferation rates are reduced, the extracellular pH is acidic, nutrient levels are low, catabolite concentrations are high and oxygen tension is low (Figure 1 ; Hahn and Little, 1972; Glinos et al, 1973) . The assay described in this study is therefore quite distinct from currently available assays used to evaluate bioreductive drugs, in that it assesses a compound's ability to be activated under conditions that mimic several properties of the tumour microenvironment, not just hypoxia. The ability to kill non-proliferating cells is essential if this class of compounds is going to be effective in the treatment of solid tumours and this is a key feature of the proposed screening programme. The use of plateau-phase cultures has several additional advantages over other models of the tumour microenvironment, such as multicellular spheroids. Firstly, it is a technically simple model in which drugs are added directly to the conditioned medium and chemosensitivity assessed using conventional assays, such as clonogenic or MTT assays. In the case of MTT assays, however, problems can occur with drugs that are either mitochondrial poisons or cause an increase in mitochondrial density or activity (Pagliacci et al, 1993; Pritsos and Vimalachandra, 1995) . Provided that short drug exposures are followed by a long drug-free recovery period (5 days in this study), then many of these problems can be eliminated. Secondly, it would detect drugs that are activated by conditions other than hypoxia alone, such as low pH, British Journal of Cancer (1997) 75(2) (1997) 75(2), [196] [197] [198] [199] [200] [201] or by combinations of environmental factors, and it would assess 'bioactivation' as opposed to classical bioreduction by hypoxia. Thirdly, cells are able to biochemically adapt to the stressful environmental conditions typically found at plateau phase. This point is particularly significant in view of the growing body of evidence suggesting that the expression of various proteins is influenced by microenvironmental conditions (Brown and Garccia, 1994) . Proteins, such as oxygen-regulated proteins (ORP) and glucoseregulated proteins (GRP), are induced under conditions of low oxygen tension and, although their specific cellular functions are not clear, they represent a series of potentially novel targets for drug design (Sciandra et al, 1984; Heacock and Sutherland, 1990; Brown and Garccia, 1994) . As conditions of low oxygen tension and poor nutrient status exist at plateau phase (Hahn and Little, 1972; Glinos et al, 1973) , these cells may therefore be biochemically similar to cells inside the tumour microenvironment, although further work is required to verify this hypothesis. Finally, there are no drug delivery problems provided that the cultures do not 'pile up' as they reach plateau phase. For any drug that is designed to be bioactivated within the tumour microenvironment, an essential characteristic of this compound is that it must be able to penetrate several layers of cells to reach its target. In the early stages of drug development, however, a drug's ability to penetrate multicell layers is not critical, as the prime objective is to identify compounds that have the potential to be bioactivated under appropriate conditions. Drug penetration barriers could be identified in more stringent secondary screens (using spheroids for example), and this problem could be addressed through either an analogue development programme or the formulation of compounds into appropriate drug delivery vehicles. The results of this study demonstrate that the proposed screening strategy can distinguish between standard anti-cancer drugs and known bioreductive agents, based upon the response of cells at different stages of the growth curve. In the case of tirapazamine, E09, mitomycin C and RSU 1069, DLD-1 cells were more sensitive to these compounds in the plateau phase of the growth curve than the same cells in exponential growth (Figures 2 and  3C ). Previous studies have reported that mitomycin C is as active against plateau-phase cells as exponentially growing cells, although this study replaced the conditioned medium with fresh medium immediately before drug exposure (Drewinko et al, 1981 ). An essential component of the assay described in this study is that drugs are added directly to conditioned medium, in the belief that drug exposures should be performed under conditions that mimic the tumour microenvironment. Nevertheless, these results suggest that if these compounds can be efficiently delivered to the tumour microenvironment, then preferential cell kill will occur at this site relative to cells under physiological conditions. This has been demonstrated in SCCVII tumours treated with RSU1069 and tirapazamine for which greater DNA damage (and cell kill with RSU 1069) has been reported in the poorly perfused regions of SCCVII tumours compared with well-perfused regions of this tumour model (Olive, 1995 a,b) . For vinblastine, doxorubicin and 5-fluorouracil, plateau-phase cells were more resistant than cells in the exponential phase ( Figure 3A) , whereas ThioTEPA and MeDZQ were equally active against both exponential and plateau-phase cells ( Figure 3B ). Several possible factors may contribute to the observed patterns of chemosensitivity, including enhanced potency under hypoxic or acidic conditions (Kennedy et al, 1985; Stratford et al, 1986; Phillips et al, 1992; Brown, 1993) . In addition, the expression and activity of DT-diaphorase, which plays a key role in the activation of quinone-based drugs (Walton et al, 1991; Ross et al, 1994) , increases under both hypoxia and as cells move into the plateau phase of the growth curve (O'Dwyer et al, 1994; Plumb and Workman, 1994) . The conditions that exist in plateau-phase cells are therefore complex, and the final outcome of chemotherapy is likely to be due to a complex interaction between several factors (such as differential drug transport, altered drug stability or activity, DNA repair status and cell kinetic factors, etc.) as opposed to a change in one parameter only. This is particularly relevant to both ThioTEPA and MeDZQ as increased activity against plateau-phase cells might be expected as a result of the increased potency of ThioTEPA in vitro under acidic conditions and elevated levels of DT-diaphorase (which activates MeDZQ) at plateau phase (Phillips et al, 1988; Ross et al, 1994) . The fact that ThioTEPA and MeDZQ are as active against plateau-phase cells as exponentially growing cells illustrates the point that the final outcome of chemotherapy is a fine balance between activation or the induction of damage on the one hand and how cells deal with potentially toxic lesions on the other. While unravelling the mechanisms responsible for these effects would provide vital information about a compound's mechanism of action, it is beyond the scope of this study.
In conclusion, plateau-phase monolayer cultures may represent a simple model of the complex microenvironment of solid tumours. The findings of this study suggest that the use of plateauphase cultures to identify potential bioactivated pro-drugs is technically feasible and may be useful as a front-line screen for this class of compounds. Further validation of this proposal is required with particular emphasis being placed on expanding the number of drugs evaluated and the number of cell lines used. It is envisaged that the interesting compounds which emerge from this initial screening programme would be evaluated in more stringent secondary screening programmes incorporating experimental models that closely mimic the three-dimensional properties of solid tumours. Several experimental models are currently available, particularly multicellular spheroids and post-confluent multicell layers (Sutherland, 1988; Pizao et al, 1993) . Both these models not only have well-characterized gradients of oxygen, cell proliferation rates, pH, nutrient status, etc. but also incorporate the important question of drug penetration and are therefore suitable for use as a secondary screening process. In addition, bioactivated drugs would have to be used in combination with standard therapies that target the well-oxygenated fraction of tumour cells, and the question of synergy between bioactivated compounds and radiotherapy or conventional chemotherapeutic agents can be addressed in these secondary screening models. As with any screening strategy, the ultimate value of any experimental model will depend upon whether activity in vitro translates into activity in vivo (Phillips et al, 1990) , and further studies to determine the predictive value of this cellular-based screening assay are currently in progress.
